The field of neurotechnology, the focus of this blog, encompasses advances in brain science (neurons), information technology (bits) and bioengineering (genes). Up for discussion and analysis: the political, economic, ethical, and social forces that will shape the future of what will be one of the most important and fascinating stories of the coming decades.
Chinese Cover of The Neuro Revolution
1 Aug 2011 at 1:40 pm
The Neuro Revolution Lands In China
1 Aug 2011 at 1:32 pm
How Neuroscience Will Change the World - My Interview on Reason.tv
21 Oct 2010 at 5:44 pm... read more
Neuroscience Hearing on Capitol Hill Wednesday Sept 29, 2pm
26 Sep 2010 at 1:10 pm
Please join me this coming Wednesday on Capitol Hill when the Oversight and Government Reform Committee has scheduled a hearing on "The Future of Neuroscience Research and Development." The hearing will be held at 2:00 p.m. in room 2203 Rayburn House Office Building, and I urge you to attend.
NIO's conversations with Congressman Kennedy and others on the Hill were the impetus for this hearing.
... read more
The Neuro Revolution Published in Japan as "Neuro Wars"
8 Sep 2010 at 1:14 pm
The Neuro Revolution was recently published in Japan! Here is the cover. They chose a slightly different title for this translation, Neuro Wars (ala Star Wars). Buy in Japan here. Looking forward to China, Korea and Brazil next!
It was while researching and writing this book over the past decade that many of my ideas around how develop social motivations systems that engender successful behavio
... read more
Neurotech 2010: Translational Researchers Highlight Innovation
2 Jul 2010 at 11:45 am
While venture capitalists have been dialing back on potentially risky early stage investments, translational researchers have been marching ahead. Government funding is pushing new discoveries forward, but sometimes the best of these languish in academic labs where companies and more adventurous investors are less likely to discover them. This year the Neurotech Development Foundation (NDF), a new
The Neuro Revolution in China Progressing
15 Jun 2010 at 11:34 amMy translator at the Science Press of China recently reached out to me for help on translating The Neuro Revolution for China. I found his correspondence interesting...
Although I have kept a good record of translation since 1978, with four national awards for my translational work in science and popular science fields, your book hitherto is the most challenging one, not only for its frontal kno ... read more
Speakers for Neurotech 2010 - Boston, May 19-20
29 Apr 2010 at 7:39 pm
We've been heads down putting together an amazing conference this year. Visit the Neurotech 2010 conference website to see full schedule. Here are this year's speakers:
Andrew Firlik General Partner, Foundation Medical Partners; Stephen Knight, Managing Partner, Fidelity Biosciences; Art Pappas, Managing Partner, Pappas Ventures; Liam Ratcliffe, Venture Partner, New Leaf Venture Partners; Casey
... read more
Giving the Brain a Voice: NIO Public Policy Tour in DC tomorrow
23 Mar 2010 at 4:29 pm
I've organized NIO's fourth annual Public Policy Tour of Washington, DC tomorrow with the help of the K&L Gates team. The one-day event will focus on high-level meetings on Capitol Hill. Meetings are scheduled with key congressmen and their staffers at their offices. We have over a dozen executives flying in who will introduce NIO and present our key proposals, including the National Neurotechnol
McGovern Institue for Brain Research at MIT Goes Web 2.0
2 Mar 2010 at 1:35 pmIt's no secret I a big fan of the McGovern Institute for Brain Research at MIT. They've launched a new website with lots of cool videos and details about the extraordinary research they are doing. Take a few minutes and wander around for yourself and become a fan on FaceBook.
... read more
The Neurodiagnostics Report 2010: Brain Imaging, Biomarkers and NeuroInformatics
9 Feb 2010 at 11:23 am
We've recently published "The Neurodiagnostics Report 2010: Brain Imaging, Biomarkers and NeuroInformatics," a report published by NeuroInsights. It is a fully updated second annual industry insider report detailing markets and emerging diagnostics in neurology and psychiatry. In addition to the massive unmet markets, long-term growth in neurodiagnostics is being driven by technology advances and
Neuropharma FDA Approvals Down in 2009
1 Feb 2010 at 12:08 pm
As we report today in this month's edition of Neurotech Insights, five of the 26 new drugs and biologics approved by the FDA were neuropharmaceuticals: Vanda/Novartis’ Fanapt for schizophrenia, Lundbeck's Sabril for infantile spasms and add-on for refractory partial seizures, Cypress/Forest’s Savella for fibromyalgia, Merck's (Organon) Saphris for bipolar and schizophrenia, and Novartis’ bra
Tel Aviv Neurotech Cluster Thrives
17 Jan 2010 at 11:18 am
Last week David Brooks wrote a spot on column about innovation in Tel Aviv, Israel. This is readily apparent in my own analysis of the global neurotechnology industry where Tel Aviv is rapidly becoming an innovation hub for next generation drugs, devices and diagnostics for the brain and nervous systems as I recently described in NIO's Neurotech Clusters 2010 report:
Tel Aviv, Israel is the amon
... read more
McGovern Institute for Brain Research at MIT - Must See 20 Minute Video
23 Dec 2009 at 2:56 pm
I highly recommend that you take 20 minutes over the next week to watch this important video that takes you on an intimate tour of the McGovern Institute for Brain Research at MIT.
As a member of the Leadership Board at the McGovern Institute, I've had the opportunity over the past several years to see first hand the brilliant, world-leading research occurring everyday at the Institute. I am ext
... read more
Neurofeedback Gets the Test
16 Dec 2009 at 11:30 am
Yesterday's Washington Post highlighted a wide scale eeg-based neurofeedback trial being conducted by the NIMH for ADHD. To date, neurofeedback for ADHD has been a cottage industry with continued attempts to bring it into the mainstream. However, lack of consensus around efficacy and its cost relative to popping pills have hindered patient adoption. Given the powerful nature of ADHD meds, it will